alexa Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease.
Immunology

Immunology

International Journal of Inflammation, Cancer and Integrative Therapy

Author(s): Baumgart DC, Wiedenmann B, Dignass AU

Abstract Share this page

Abstract BACKGROUND: Oral tacrolimus, approved for the prophylaxis of organ rejection in liver or kidney transplants, has been reported to be effective in anecdotal cases of refractory inflammatory bowel disease. AIM: To evaluate the usefulness of low-dose oral tacrolimus in refractory inflammatory bowel disease. METHODS: Thirty-one adult Caucasian patients with steroid-dependent (n = 15) or steroid-refractory (n = 16) inflammatory bowel disease (Crohn's disease, n = 6; ulcerative colitis, n = 23; pouchitis, n = 2) were enrolled. Tacrolimus (0.1 mg/kg body weight per day) was administered orally in 30 patients and initially intravenously in one patient (0.01 mg/kg body weight per day), aiming for serum trough levels of 4-6 ng/mL. The median treatment duration was 12 months (range, 1-137 months). RESULTS: Twenty-eight patients (90.3\%) experienced a clinical and laboratory response and 20 (64.5\%) went into remission. One ulcerative colitis patient and two Crohn's disease patients did not improve. Three ulcerative colitis patients (9.7\%) were colectomized at 1, 12 and 24 months after tacrolimus initiation. In 19 of 23 patients (82.6\%) taking steroids, steroids were reduced or discontinued. Side-effects included a temporary rise of creatinine (n = 3, 9.7\%), tremor or paraesthesias (n = 3, 9.7\%), hyperkalaemia (n = 1, 3.2\%), hypertension (n = 1, 3.2\%) and an opportunistic infection (n = 1, 3.2\%). CONCLUSION: Oral tacrolimus is safe and effective in refractory inflammatory bowel disease.
This article was published in Aliment Pharmacol Ther and referenced in International Journal of Inflammation, Cancer and Integrative Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords